Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial
Autores: Zhao L, Cheng Z, Lu Y, Liu M, Chen H, et al.
Revista
JAMA
Año
2024
Citas
300
Type
Clinical Trial
Subject
Human
Condition
Obesity / Type 2 Diabetes
TL;DR
SURMOUNT-CN trial: tirzepatide demonstrated efficacy for weight reduction in Chinese adults with obesity or overweight with comorbidities across 29 centers.
Ver Artículo
DOI: 10.1001/jama.2024.9217
Abstract
Obesity has become a global public health concern and China has the largest number of affected people worldwide.. To assess the efficacy and safety of treatment with tirzepatide for weight reduction in Chinese adults with obesity or overweight and weight-related comorbidities.. This randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 29 centers in China from.